NEW YORK (GenomeWeb News) – Sequenta has completed a Series C financing round, raising $20 million, it said on Tuesday.

Proceeds will go toward the commercial scale-up and clinical validation of its next-generation sequencing-based ClonoSight Test for minimal residual disease in leukemia and lymphoma.

Foresite Capital Management led the round, and all inside investors participated, Sequenta said, including MDV and Index Ventures. In addition, Jim Tananbaum, managing director of Foresite Capital, has joined Sequenta's board.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.